Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
Danyelza (naxitamab-gqgk)
i
Other names:
Hu3F8, Hu3F8 (GD2), Hu3F8-Fce, humanized 3F8 , humanized anti-GD2 antibody
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(1)
News
Trials
Company:
Nobelpharma, SciClone, Takeda, Y-mAbs Therap
Drug class:
GD2 ganglioside inhibitor
Related drugs:
‹
dinutuximab beta (2)
dinutuximab (1)
BCD-245 (0)
TRBS07 (0)
GD2-GD3 Vaccine (0)
GD2-SADA (0)
KUR-501 (0)
Hu14.18K322A (0)
APN301 (0)
GD2xCD3 (0)
dinutuximab beta (2)
dinutuximab (1)
BCD-245 (0)
TRBS07 (0)
GD2-GD3 Vaccine (0)
GD2-SADA (0)
KUR-501 (0)
Hu14.18K322A (0)
APN301 (0)
GD2xCD3 (0)
›
Associations
(1)
News
Trials
VERI cancer hierarchy
Reset Filters
No biomarker
Neuroblastoma
No biomarker
Neuroblastoma
naxitamab-gqgk
Sensitive: A1 - Approval
naxitamab-gqgk
Sensitive
:
A1
naxitamab-gqgk
Sensitive: A1 - Approval
naxitamab-gqgk
Sensitive
:
A1
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login